Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Gozetotide→

Gozetotide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1366302-52-4
Molecular formula
C44H62N6O17
Molecular weight
947 g/mol
Drug class
PSMA-targeting liganddiagnostic radiopharmaceutical component for gallium-68 PET imaging
Mechanism of action
The Glu-urea-Lys(Ahx) peptide ligand binds prostate-specific membrane antigen (PSMA) on prostate epithelial cells and commonly overexpressed on prostate cancer cells. When conjugated to the HBED-CC chelator and radiolabelled with gallium-68, the resulting radioconjugate enables PET visualisation of PSMA-expressing lesions.
Indications / reported uses
  • Used as the active ligand in gallium Ga-68 gozetotide (PSMA-11) injection for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated PSA.
  • The unlabelled ligand is not itself a radioactive imaging agent; diagnostic imaging requires the labelled gallium-68 product.

Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/locametz · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=357655a4-b3ee-4ea1-a1ea-50d4686546bb · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gallium-ga-68-gozetotide · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Gozetotide Environmental Risk Assessment (ERA) (the Gozetotide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.